Related Experiment Video
Updated: Feb 12, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Cellular and Novel Immunotherapies for Classic Hodgkin Lymphoma
Daniel Klein Reef1, Natalie Sophia Grover1
1Division of Hematology, Department of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Abstract:
The CD30 antibody-drug conjugate, brentuximab vedotin, and PD-1 inhibitors, nivolumab and pembrolizumab have transformed the care of patients with Hodgkin lymphoma and have been incorporated into earlier lines of therapy. However, there are limited treatment options for patients with relapsed/refractory disease whose disease has progressed after brentuximab vedotin and checkpoint inhibitors. Novel immunotherapies for patients with relapsed/refractory Hodgkin lymphoma include CAR-T products, EBV-specific T cells, bispecific antibodies, and checkpoint inhibitor combinations. We review the rationale for each and summarize safety, efficacy, and progress in clinical development.
Related Concept Videos
Classical Conditioning
Ivan Pavlov observed that dogs...
Tumor Immunotherapy
Principles of Classical Conditioning
During the...
Classical Conditioning in Daily Life
John B. Watson and Rosalie Rayner famously demonstrated the development of fear through classical conditioning in their experiment with Little Albert. They paired the...
Real-World Application of Classical Conditioning
Higher-order, or second-order, conditioning occurs when a neutral stimulus becomes associated with an already established conditioned stimulus through repeated pairings. For instance, if a dog has been...
Cellular Differentiation
A zygote is a...

